Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 160 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Topiramate Clear all
Terminated Phase 4 Interventional

Efficacy of Pharmacotherapy to Enhance Weight Loss Following Sleeve Gastrectomy

NCT03603080
View directory record Official record
Conditions
Obesity
Interventions
Administration of weight loss drug (Metformin or Topiramate)
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 1, 2026, 7:26 PM EDT
Recruiting Phase 4 Interventional

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

NCT07213466
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
Interventions
Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 1, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents

NCT01110434
View directory record Official record
Conditions
Cannabis Abuse, Cannabis Dependence
Interventions
Topiramate, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
15 Years to 20 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 1, 2026, 7:26 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms

NCT01641445
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Topiramate, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
14 Years to 24 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 1, 2026, 7:26 PM EDT
Completed Phase 1 Interventional

Preventing Brain Injury in Infants With Congenital Heart Disease

NCT01426542
View directory record Official record
Conditions
Cyanotic Congenital Heart Disease
Interventions
Topiramate, No medication, but routine heart surgery
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 2 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 1, 2026, 7:26 PM EDT
Completed Phase 2 Interventional

Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)

NCT02659475
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
PHEN/TPM ER (Qsymia®)
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Sep 1, 2026, 7:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate

NCT03308669
View directory record Official record
Conditions
Healthy
Interventions
Lasmiditan, Placebo, Topiramate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 1, 2026, 7:26 PM EDT
Not listed Phase 3 Interventional

Novel Pharmacotherapy for Dual Dependence

NCT00448825
View directory record Official record
Conditions
Alcohol Dependence, Cocaine Dependence
Interventions
Topiramate + Cognitive Behavioral Therapy, Placebo + Cognitive Behavioral Therapy
Drug
Lead sponsor
Bankole Johnson
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Sep 1, 2026, 7:26 PM EDT
Completed Phase 4 Interventional Results available

A Toolbox Approach to Obesity Treatment in Primary Care

NCT01922934
View directory record Official record
Conditions
Obesity
Interventions
Commercial weight loss program, Colorado Weigh, Meal replacements, Obesity pharmacotherapy, Recreation center passes
Behavioral · Dietary Supplement · Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 80 Years
Enrollment
4,730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 1, 2026, 7:26 PM EDT
Withdrawn Phase 4 Interventional

Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department

NCT02945839
View directory record Official record
Conditions
Migraine
Interventions
Preventative Medication (PM), Enhanced Usual Care, PMR (progressive muscle relaxation therapy)
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 1, 2026, 7:26 PM EDT
Terminated Phase 4 Interventional

A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache

NCT00203190
View directory record Official record
Conditions
Cluster Headache
Interventions
Topiramate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2009 · Synced Sep 1, 2026, 7:26 PM EDT
Not listed Phase 2 Interventional

A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis

NCT00217295
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Avonex and Topamax
Drug
Lead sponsor
Multiple Sclerosis Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2005 · Synced Sep 1, 2026, 7:26 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of Intravenous Topiramate in Adult Patients

NCT00753493
View directory record Official record
Conditions
Epilepsy, Migraines
Interventions
intravenous topiramate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 1, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

NCT01191086
View directory record Official record
Conditions
Epilepsy
Interventions
USL255
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
16
States / cities
Phoenix, Arizona • Ventura, California • Gainsville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Sep 1, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults

NCT00554216
View directory record Official record
Conditions
Obesity
Interventions
VI-0521, Placebo matched phentermine/topiramate
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
San Diego, California • Ridgefield, Connecticut • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 1, 2026, 7:26 PM EDT
Completed Phase 4 Interventional Results available

Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine

NCT00394095
View directory record Official record
Conditions
Bipolar Disorder, Weight Gain
Interventions
Topiramate, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 1, 2026, 7:26 PM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 1, 2026, 7:26 PM EDT
Withdrawn Phase 3 Interventional

The Use of Anticonvulsants for Treatment of Patients With Alcohol Dependence and Post Traumatic Stress Disorder

NCT00571246
View directory record Official record
Conditions
Alcohol Dependence, Post Traumatic Stress Disorder
Interventions
Topiramate, lamotrigine, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 15, 2020 · Synced Sep 1, 2026, 7:26 PM EDT
Recruiting Phase 2 Interventional

Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD

NCT03667846
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Alcohol Use Disorder
Interventions
Topiramate, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 1, 2026, 7:26 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity

NCT05834062
View directory record Official record
Conditions
Obesity, Adolescent
Interventions
Qsymia and lifestyle management therapy, Placebo and lifestyle management therapy
Drug · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 22 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 1, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals

NCT00300742
View directory record Official record
Conditions
Alcohol Dependence, Binge Eating
Interventions
Topiramate
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 1, 2026, 7:26 PM EDT
Completed Early Phase 1 Interventional Results available

Pharmacokinetics and Pharmacodynamics of Topiramate for Weight Loss in Youth: PHARMATOP

NCT04986631
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Topiramate Tablets
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 1, 2026, 7:26 PM EDT
Completed Phase 4 Interventional Results available

A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents

NCT02714062
View directory record Official record
Conditions
Pediatric Obesity, Childhood Obesity
Interventions
Placebo, VI-0521 Mid Dose, VI-0521 Top Dose
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Marrero, Louisiana • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 1, 2026, 7:26 PM EDT